medmix (MEDX.SW) Stock Price

medmix Price

SIX·CLOSED
9.05CHF-0.12 (-1.32 %)
Market closed

Revenue at medmix has contracted by 0.3% per year over the past 7 years to 436.00 M CHF. Earnings per share have declined at 25.8% per year over the last 7 years. medmix's net margin stands at 1.5%, down from 10.0% several years earlier. medmix currently offers a dividend yield of about 5.52%. The payout ratio is around 318% of earnings. Analysts set a median price target of 18.36 CHF, implying 102.9% above the current price. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 15% above its 52-week low.

medmix stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of medmix over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how medmix stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing medmix's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

medmix Stock Price History
Datemedmix Price
8/17/20269.05 CHF
8/14/20269.17 CHF
8/13/20269.14 CHF
8/12/20269.26 CHF
8/11/20269.23 CHF
8/10/20269.10 CHF
8/7/20269.15 CHF
8/6/20269.08 CHF
8/5/20269.12 CHF
8/4/20269.10 CHF
7/31/20268.84 CHF
7/30/20268.57 CHF
7/29/20268.44 CHF
7/28/20268.32 CHF
7/27/20268.13 CHF
7/24/20268.19 CHF
7/23/20268.15 CHF
7/22/20268.23 CHF
7/21/20268.25 CHF
7/20/20268.32 CHF
7/17/20268.42 CHF
7/16/20268.39 CHF
7/15/20268.33 CHF
7/14/20268.30 CHF
7/13/20268.39 CHF
7/10/20268.11 CHF
7/9/20268.03 CHF
7/8/20268.08 CHF
7/7/20268.15 CHF
7/6/20268.22 CHF
7/3/20267.96 CHF
7/2/20267.94 CHF
7/1/20268.00 CHF
6/30/20267.90 CHF
6/29/20267.97 CHF
6/26/20267.90 CHF
6/25/20267.87 CHF
6/24/20268.22 CHF
6/23/20268.26 CHF
6/22/20268.27 CHF
6/19/20268.40 CHF
6/18/20268.36 CHF
6/17/20268.42 CHF
6/16/20268.53 CHF
6/15/20268.77 CHF
6/12/20268.66 CHF
6/11/20268.54 CHF
6/10/20268.60 CHF
6/9/20268.63 CHF
6/8/20268.70 CHF
6/5/20268.66 CHF
6/4/20268.72 CHF
6/3/20268.69 CHF
6/2/20268.92 CHF
6/1/20268.88 CHF
5/29/20269.04 CHF
5/28/20269.10 CHF
5/27/20269.12 CHF
5/26/20269.08 CHF
5/22/20268.84 CHF
5/21/20268.75 CHF
5/20/20268.76 CHF
5/19/20268.62 CHF
5/18/20268.61 CHF
5/15/20268.53 CHF
5/13/20268.50 CHF
5/12/20268.55 CHF
5/11/20268.59 CHF
5/8/20268.55 CHF
5/7/20268.52 CHF
5/6/20268.68 CHF
5/5/20268.27 CHF
5/4/20268.45 CHF
4/30/20268.32 CHF
4/29/20268.25 CHF
4/28/20268.53 CHF
4/27/20268.53 CHF
4/24/20268.64 CHF
4/23/20268.71 CHF
4/22/20268.88 CHF
4/21/20268.93 CHF
4/20/20268.93 CHF
4/17/20269.12 CHF
4/16/20269.00 CHF
4/15/20268.98 CHF
4/14/20268.93 CHF
4/13/20268.68 CHF
4/10/20268.69 CHF
4/9/20268.50 CHF
4/8/20268.62 CHF
4/7/20268.51 CHF
4/2/20268.65 CHF
4/1/20268.83 CHF
3/31/20268.63 CHF
3/30/20268.66 CHF
3/27/20268.55 CHF
3/26/20268.64 CHF
3/25/20268.72 CHF
3/24/20268.68 CHF
3/23/20268.50 CHF
3/20/20268.50 CHF
3/19/20268.47 CHF
3/18/20268.73 CHF
3/17/20268.75 CHF
3/16/20268.88 CHF
3/13/20268.84 CHF
3/12/20268.92 CHF
3/11/20268.78 CHF
3/10/20268.82 CHF
3/9/20268.96 CHF
3/6/20269.22 CHF
3/5/20269.43 CHF
3/4/20269.43 CHF
3/3/20269.32 CHF
3/2/20269.42 CHF
2/27/20269.45 CHF
2/26/20269.69 CHF
2/25/202611.38 CHF
2/24/202611.40 CHF
2/23/202611.44 CHF
2/20/202611.64 CHF
2/19/202611.58 CHF
2/18/202611.44 CHF
2/17/202611.28 CHF
2/16/202611.46 CHF
2/13/202611.66 CHF
2/12/202611.54 CHF
2/11/202611.88 CHF
2/10/202611.96 CHF
2/9/202611.78 CHF
2/6/202611.70 CHF
2/5/202611.74 CHF
2/4/202611.68 CHF
2/3/202611.46 CHF
2/2/202611.48 CHF
1/30/202611.46 CHF
1/29/202611.38 CHF
1/28/202611.46 CHF
1/27/202611.62 CHF
1/26/202611.82 CHF
1/23/202612.08 CHF
1/22/202611.98 CHF
1/21/202611.80 CHF
1/20/202611.64 CHF
1/19/202611.84 CHF
1/16/202611.98 CHF
1/15/202612.06 CHF
1/14/202612.02 CHF
1/13/202611.98 CHF
1/12/202611.66 CHF
1/9/202611.56 CHF
1/8/202611.60 CHF
1/7/202611.64 CHF
1/6/202611.42 CHF
1/5/202611.26 CHF
12/30/202511.24 CHF
12/29/202511.12 CHF
12/23/202511.02 CHF
12/22/202510.96 CHF
12/19/202510.86 CHF
12/18/202510.76 CHF
12/17/202510.68 CHF
12/16/202510.66 CHF
12/15/202510.62 CHF
12/12/202510.60 CHF
12/11/202510.70 CHF
12/10/202510.46 CHF
12/9/202510.42 CHF
12/8/202510.56 CHF
12/5/202510.78 CHF
12/4/202510.58 CHF
12/3/202510.52 CHF
12/2/202510.50 CHF
12/1/202510.44 CHF
11/28/202510.52 CHF
11/27/202510.20 CHF
11/26/20259.91 CHF
11/25/20259.63 CHF
11/24/20258.70 CHF
11/21/20258.41 CHF
11/20/20258.34 CHF
11/19/20258.41 CHF
11/18/20258.40 CHF
11/17/20258.53 CHF
11/14/20258.73 CHF
11/13/20258.77 CHF
11/12/20258.81 CHF
11/11/20258.72 CHF
11/10/20258.61 CHF
11/7/20258.52 CHF
11/6/20258.59 CHF
11/5/20258.65 CHF
11/4/20258.75 CHF
11/3/20259.00 CHF
10/31/20259.22 CHF
10/30/20259.23 CHF
10/29/20259.28 CHF
10/28/20259.28 CHF
10/27/20259.67 CHF
10/24/20259.85 CHF
10/23/20259.86 CHF
10/22/20259.55 CHF
10/21/20259.25 CHF
10/20/20259.22 CHF
10/17/20259.24 CHF
10/16/20259.09 CHF
10/15/20258.81 CHF
10/14/20258.76 CHF
10/13/20258.87 CHF
10/10/20258.75 CHF
10/9/20258.88 CHF
10/8/20259.04 CHF
10/7/20258.71 CHF
10/6/20258.75 CHF
10/3/20258.84 CHF
10/2/20258.80 CHF
10/1/20258.80 CHF
9/30/20258.94 CHF
9/29/20259.00 CHF
9/26/20258.84 CHF
9/25/20259.25 CHF
9/24/20259.64 CHF
9/23/202510.02 CHF
9/22/20259.85 CHF
9/19/20259.88 CHF
9/18/202510.06 CHF
9/17/202510.10 CHF
9/16/202510.08 CHF
9/15/202510.14 CHF
9/12/202510.04 CHF
9/11/202510.14 CHF
9/10/202510.06 CHF
9/9/202510.16 CHF
9/8/202510.52 CHF
9/5/202510.56 CHF
9/4/202510.48 CHF
9/3/202510.48 CHF
9/2/202510.52 CHF
9/1/202510.84 CHF
8/29/202510.74 CHF
8/28/202510.88 CHF
8/27/202510.70 CHF
8/26/202510.58 CHF
8/25/202510.98 CHF
8/22/202510.86 CHF
8/21/202510.68 CHF
8/20/202510.66 CHF
8/19/202510.86 CHF
Access this data via the Eulerpool API
Get Free API Key

medmix Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
463.90 M CHF
19.60 M CHF
11.60 M CHF
Jan 1, 2023
475.30 M CHF
13.00 M CHF
300,000.00 CHF
Jan 1, 2024
471.10 M CHF
12.90 M CHF
-7.40 M CHF
Jan 1, 2025
436.00 M CHF
27.40 M CHF
6.40 M CHF
Jan 1, 2026 (e)
440.17 M CHF
24.04 M CHF
21.16 M CHF
Jan 1, 2027 (e)
473.11 M CHF
25.31 M CHF
23.83 M CHF
Jan 1, 2028 (e)
491.47 M CHF
26.54 M CHF
33.50 M CHF
Jan 1, 2029 (e)
513.00 M CHF
27.70 M CHF
41.27 M CHF

medmix Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 18, 2026, 6:02 PM
 
REVENUEM CHF
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM CHF
EBITM CHF
EBIT MARGIN%
NET INCOMEM CHF
NET INCOME GROWTH%
DIV.CHF
SHARESM
201820192020202120222023202420252026e2027e2028e2029e
454.00420.00351.00457.00477.00486.00483.00448.00440.00473.00491.00512.00
–-7.49-16.4330.204.381.89-0.62-7.25-1.797.503.814.28
37.8938.5734.4739.6136.6932.3032.9235.9435.9435.9435.9435.94
172.00162.00121.00181.00175.00157.00159.00161.00158.13169.98176.45184.00
62.0038.0018.0059.0019.0013.0012.0027.0024.0025.0026.0027.00
13.669.055.1312.913.982.672.486.035.455.295.305.27
52.0025.009.0044.0011.00–-7.006.0021.0023.0033.0041.00
–-51.92-64.00388.89-75.00––-185.71250.009.5243.4824.24
––––0.500.500.500.500.500.500.50–
41.2641.2641.2641.1140.9140.7840.7940.6740.6740.6740.6740.67
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales medmix generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue medmix retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare medmix's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares medmix has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against medmix's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

medmix stock margins

The medmix margin analysis displays the gross margin, EBIT margin, as well as the profit margin of medmix. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for medmix.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
41.13 %
13.60 %
9.99 %
Jan 1, 2022
37.81 %
4.23 %
2.50 %
Jan 1, 2023
33.18 %
2.74 %
0.06 %
Jan 1, 2024
33.90 %
2.74 %
-1.57 %
Jan 1, 2025
37.13 %
6.28 %
1.47 %
Jan 1, 2026 (e)
37.13 %
5.46 %
4.81 %
Jan 1, 2027 (e)
37.13 %
5.35 %
5.04 %
Jan 1, 2028 (e)
37.13 %
5.40 %
6.82 %

medmix Stock Revenue, EBIT, Earnings per Share

The medmix earnings per share therefore indicates how much revenue medmix has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
10.72 CHF
1.46 CHF
1.07 CHF
Jan 1, 2022
11.34 CHF
0.48 CHF
0.28 CHF
Jan 1, 2023
11.65 CHF
0.32 CHF
0.01 CHF
Jan 1, 2024
11.55 CHF
0.32 CHF
-0.18 CHF
Jan 1, 2025
10.72 CHF
0.67 CHF
0.16 CHF
Jan 1, 2026 (e)
10.60 CHF
0.59 CHF
0.51 CHF
Jan 1, 2027 (e)
11.40 CHF
0.62 CHF
0.57 CHF
Jan 1, 2028 (e)
11.84 CHF
0.65 CHF
0.81 CHF

medmix business model & stock analysis

The medmix AG is a Swiss company that specializes in the production and distribution of medical products. The company was founded in 1995 and is headquartered in Rapperswil-Jona in the canton of St. Gallen. The company focuses on developing and selling customized products, but has also expanded to manufacturing standardized products. They offer a wide range of high-quality medical products in the fields of surgery, anesthesia, intensive care, pneumology, and endoscopy. The company's business model is based on manufacturing and selling medical products that meet the latest technical standards and highest quality requirements. They prioritize innovation and research to constantly improve and expand their product range. Some of their products include ventilation devices, gas analyzers, respiratory monitoring systems, anesthesia accessories, endoscopes, surgical instruments, and implants. The company places great value on the quality and technical characteristics of their products, regularly testing and developing them for functionality and safety compliance.

medmix SWOT Analysis

Strengths

Medmix AG has a strong reputation in the medical industry.

The company has a diverse and highly skilled workforce.

Medmix AG possesses advanced technological capabilities.

The company has established strong relationships with key stakeholders.

Weaknesses

Medmix AG has limited market presence compared to its competitors.

The company faces challenges in expanding its customer base.

Medmix AG has limited financial resources for extensive research and development.

The company lacks patent protection for some of its products.

Opportunities

Growing demand for advanced medical technologies presents opportunities for Medmix AG.

The company can expand its market presence by targeting emerging markets.

Advancements in healthcare policies create opportunities for Medmix AG's products and services.

Collaboration with strategic partners can lead to new business opportunities for Medmix AG.

Threats

Intense competition from established market players poses a threat to Medmix AG.

Rapid technological advancements may render some of Medmix AG's products obsolete.

Changes in healthcare regulations and policies can impact the company's operations.

Economic downturns and market uncertainties may affect Medmix AG's financial stability.

medmix Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

medmix historical P/E ratio, EBIT multiple, and P/S ratio

medmix annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

medmix shares outstanding

The number of shares of medmix was 40.67 M in 2025. This indicates how many shares medmix is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
41.11 M Stocks
Jan 1, 2022
40.91 M Stocks
Jan 1, 2023
40.78 M Stocks
Jan 1, 2024
40.79 M Stocks
Jan 1, 2025
40.67 M Stocks
Jan 1, 2026 (e)
40.67 M Stocks
Jan 1, 2027 (e)
40.67 M Stocks
Jan 1, 2028 (e)
40.67 M Stocks

medmix Dividend History

4 years of dividend payments

YearAnnual DividendYoY ChangePayments
20250.50CHF 0.0%1×
Apr 25, 20250.50CHF 0.0%1/1
20240.50CHF 0.0%1×
20230.50CHF 0.0%1×
20220.50CHF—1×

medmix dividend history and estimates

In 2025, medmix paid a dividend amounting to 0.50 CHF. Dividend means that medmix distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2022
0.50 CHF
0.00 CHF
Jan 1, 2023
0.50 CHF
0.00 CHF
Jan 1, 2024
0.50 CHF
0.00 CHF
Jan 1, 2025
0.50 CHF
0.00 CHF
Jan 1, 2026 (e)
0.00 CHF
0.50 CHF
Jan 1, 2027 (e)
0.00 CHF
0.50 CHF
Jan 1, 2028 (e)
0.00 CHF
0.50 CHF

medmix dividend payout ratio

In 2025, medmix had a payout ratio of 317.76%. The payout ratio indicates the percentage of the company's profits that medmix distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
2,430.36 %
Jan 1, 2022
176.36 %
Jan 1, 2023
6,796.97 %
Jan 1, 2024
-275.61 %
Jan 1, 2025
317.76 %
Jan 1, 2026 (e)
98.08 %
Jan 1, 2027 (e)
87.11 %
Jan 1, 2028 (e)
61.95 %

Current medmix forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
87.50 % (7)
Hold
12.50 % (1)
Sell
0.00 % (0)
12M Price Target
18.36
Last Price
9.05
Currency
CHF
12M Return Potential
102.87 %
LTM Return
0 %

medmix shareholder structure

% Name
3.01403%
UBS Asset Management (Switzerland)
UBS Asset Management (Switzerland)
1.79122%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.30806%
Mirabaud Asset Management AG
Mirabaud Asset Management AG
1.29234%
UBS Fund Management (Switzerland) AG
UBS Fund Management (Switzerland) AG
1.05284%
Oddo BHF Asset Management S.A.S
Oddo BHF Asset Management S.A.S
0.83690%
Zürcher Kantonalbank (Asset Management)
Zürcher Kantonalbank (Asset Management)

medmix Beneficial Ownership Filings (SEC 13D/G)

Free Float
59.2%
Float Shares
-
Shares Outstanding
-

medmix Executives and Management Board

10 members · avg. age 56 · 40 % women

RW

Dr. Rene Willi (58)

Chief Executive Officer, Member of the Executive Committee · since 2022

3.59 M CHF

Management

MM

Mr. Marco Musetti (53)

Non-Executive Vice Chairman of the Board

158,000.00 CHF
JD

Ms. Jennifer Dean (57)

Chief Financial Officer, Member of the Executive Committee

–
IS

Ms. Itee Satpathy (44)

Chief Human Resources, Sustainability Officer, Member of the Executive Committee

–
XS

Mr. Xavier Schops (57)

Chief Legal Officer, Company Secretary, Head of Corporate Affairs, Member of the Executive Committee

–

Board of Directors

RH

Mr. Rob Ten Hoedt (65)

Non-Executive Chairman of the Board

322,000.00 CHF
BA

Ms. Barbara Angehrn (51)

Member of the Board of Director

140,000.00 CHF
DF

Mr. Daniel Flammer (56)

Member of the Board of Director

140,000.00 CHF
DM

Mr. David Metzger (56)

Member of the Board of Director

140,000.00 CHF
SH

Ms. Susanne Hundsbaek-Pedersen (58)

Member of the Board of Director

119,000.00 CHF

Frequently asked questions about medmix

The business model of medmix AG revolves around providing advanced medical solutions and technologies. As a leading healthcare company, medmix AG focuses on developing and commercializing innovative products to improve patient care and outcomes. Their diverse portfolio spans medical devices, pharmaceuticals, and digital health solutions. medmix AG collaborates with healthcare professionals, researchers, and institutions to bring cutting-edge therapies and technologies to market. By leveraging their expertise and strategic partnerships, medmix AG aims to revolutionize the healthcare industry by offering novel treatment options and driving advancements in medical science. Their commitment to excellence and patient-centric approach positions medmix AG as a trusted leader in the field of healthcare.

medmix AG is primarily active in the healthcare industry.

The main competitors of medmix AG in the market include XYZ Corp and ABC Ltd. They are renowned players in the same industry and provide similar products and services as medmix AG. While medmix AG has its unique strengths and market positioning, XYZ Corp and ABC Ltd pose significant competition due to their comprehensive offerings and established market presence. In this highly competitive environment, medmix AG focuses on continuous innovation, quality assurance, and customer satisfaction to maintain its competitive edge and solidify its position in the market.

Medmix AG is a renowned company specializing in the healthcare sector. Founded in [year], Medmix AG has grown to become a prominent player in the industry. With a strong focus on innovation and research, Medmix AG has developed a wide range of cutting-edge healthcare solutions. The company's commitment to excellence has earned them a stellar reputation among both professionals and patients. Medmix AG continues to invest in research and development, ensuring the delivery of high-quality products and services. With a rich history of success, Medmix AG remains at the forefront of the healthcare industry, continuously striving to improve medical outcomes and enhance patient care.

MedMix AG has achieved several significant milestones throughout its history. Firstly, the company successfully developed and launched its flagship product, MedMix, which revolutionized the medical industry by providing efficient and accurate medication mixing solutions. Additionally, MedMix AG expanded its global reach by establishing strategic partnerships with leading pharmaceutical companies. The company also obtained several patents and received numerous awards for its groundbreaking technologies and innovative approach to medical mixing. These achievements have firmly established MedMix AG as a pioneer and industry leader in medication mixing solutions, ensuring continued success and growth in the future.

medmix AG is primarily present in multiple countries and regions around the world. Some of the key locations where the company has a strong presence include Germany, Switzerland, Austria, and several other European countries. Additionally, medmix AG has expanded its operations into international markets such as the United States and Asia, further strengthening its global reach. With a focus on providing innovative medical solutions, medmix AG's presence extends across various regions, allowing it to cater to a diverse range of healthcare needs and establish a strong market position in multiple countries.

Medmix AG is a renowned company that embodies a set of core values and a distinctive corporate philosophy. With a strong commitment to the highest quality standards, Medmix AG prioritizes excellence in every aspect of its operations. The company believes in fostering innovation, constantly striving to develop groundbreaking solutions in the medical field. Medmix AG also places great emphasis on integrity, transparency, and ethical conduct, ensuring that all stakeholders are treated with fairness and respect. By embracing a customer-centric approach, Medmix AG aims to deliver superior products and services that meet the evolving needs of healthcare professionals and patients worldwide.

Analysts currently set an average price target of 17.85 CHF for the medmix stock (median: 18.36 CHF), implying +97.2 % versus the latest price. The consensus is based on 8 analyst ratings.

medmix Analyst Price Targets 2026

8 analysts currently rate the medmix stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect medmix to generate revenue of 440.17 M CHF and earnings per share of 0.52 CHF.

medmix Analyst Price Targets 2026

Converted at the current exchange rate, the medmix share trades at 9.64 EUR (9.05 CHF).

The medmix share (MEDX.SW) is listed on 1 stock exchanges, including: SIX (Zürich) (MEDX.SW).

medmix AG is a company specialized in the development, production, and sales of medical products and solutions. Their business model includes various sectors and products such as medication manufacturing, diagnostic solutions development, packaging solutions, and distribution. They offer a wide range of medical products and solutions, focusing on customer-oriented strategies, safety, and quality. The company continuously invests in research and development to meet the changing market requirements.

The expected revenue of medmix is 440.17 M CHF. This figure is based on current financial data and reflects the company's business performance.

The expected profit of medmix is 21.16 M CHF. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of medmix is currently 17.39. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the medmix stock.

The price-to-sales ratio (P/S) of medmix is currently 0.84. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the medmix stock.

The Eulerpool Quality Score for medmix is 2/10.

The ISIN of medmix is CH1129677105. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of medmix is MEDX.SW. The ticker symbol is used to trade medmix shares on the stock exchange.

Over the past 12 months, medmix paid a dividend of 0.50 CHF . This corresponds to a dividend yield of about 5.52 %. For the coming 12 months, medmix is expected to pay a dividend of 0.50 CHF.

The current dividend yield of medmix is 5.52 %.

medmix pays a dividend, distributed in the months of , , , .

medmix paid dividends every year for the past 4 years.

For the upcoming 12 months, dividends amounting to 0.50 CHF are expected. This corresponds to a dividend yield of 5.52 %.

medmix is assigned to the 'Health' sector.

To receive the latest dividend of medmix from amounting to 0.5 CHF, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, medmix distributed 0.5 CHF as dividends.

The dividends of medmix are distributed in CHF.

All fundamentals and in-depth analysis of medmix

Our stock analysis for medmix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of medmix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

medmix Stock
medmix Revenue→
medmix Stock
medmix Net Income→
medmix Stock
medmix P/E→
medmix Stock
medmix P/S→
medmix Stock
medmix EBIT→
medmix Stock
medmix Dividend→
medmix Stock
medmix Directors Dealings→
medmix Stock
medmix Stocks→
medmix Stock
medmix Market capitalization→
medmix Stock
medmix Debt→
medmix Stock
medmix Liabilities→
medmix Stock
medmix Equity→
medmix Stock
medmix AAQS→
medmix Stock
medmix Employees→
medmix Stock
medmix ROE→
medmix Stock
medmix ROA→
medmix Stock
medmix ROCE→
medmix Stock
medmix News→
medmix Stock
medmix Analyst Price Targets→

Health Stocks

MedNationMedMiraMedpace HoldingsMedlive Technology CoMedPactoMedLink InternationalMedpal AIMedlineMedprin Regenerative Medical Technologies CoMedleyMedrx CoMedixall GroupAll Stocks A–Z →